We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 18, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PayPal Holdings, Inc. (PYPL - Free Report) , Zoetis Inc. (ZTS - Free Report) , CSX Corp. (CSX - Free Report) ,Northrop Grumman Corp. (NOC - Free Report) , and The Kraft Heinz Co. (KHC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for PayPal, Zoetis and CSX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc., Zoetis Inc., and CSX Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
PayPal shares have declined -61.8% over the past year against the Zacks Internet - Software industry's decline of -47.3% as sentiment has soured on growth stocks whose full profitability is way out in the future in a rising interest rate environment. The Zacks analyst points out to intensifying competition in the digital payment market as a headwind for the company's market position.
However, PayPal continues to benefit from robust growth in total payments volume owing to increasing net new active accounts. Further, strengthening customer engagement on the company's platform is a major positive.
Venmo's improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind.
Shares of Zoetis have outperformed the Zacks Medical - Drugs industry over the past year (+14.2% vs. -22.4%). The Zacks analyst believes that an innovative portfolio of petcare parasiticides, including Simparica Trio and dermatology products (Apoquel and Cytopoint) will help the company's continued momentum. The uptake of Librela and Solensia, its new monoclonal antibody (mAb) therapies for osteoarthritis (OA) pain in dogs and cats, is encouraging in Europe and should boost growth. Zoetis' companion animal portfolio maintains momentum.
The launch of innovative products (ProHeart, Librela, Revolution Plus and many vaccines) bolstered the portfolio and should fuel growth in the upcoming quarters. However, the livestock portfolio has been affected by generic competition across cattle, poultry, swine, and dairy consumer markets in the United States. Pricing pressure will continue to hurt sales, which is a woe.
Shares of CSX have outperformed the Zacks Transportation - Rail industry over the past year (+7.7% vs. +4.9%). The Zacks analyst believes that due to healthy freight environment, CSX is benefiting from higher export coal volumes, international intermodal shipments, and pricing gains. The company's Volumes rose 6% in 2021, leading to an 18% jump in revenues, efforts to reward shareholders are encouraging. In February, CSX hiked its dividend by 7.5%.
The company returned over $3.7 billion to shareholders via dividends and share buybacks. However, supply chain disruptions are hurting CSX's operations. Weakness in the merchandise segment due to lower automotive volumes is concerning. High costs, primarily due to escalating fuel expenses, pose a threat to CSX's bottom line. The company's high capital expenditures are also worrisome.
Other noteworthy reports we are featuring today include Northrop Grumman Corp., and The Kraft Heinz Co..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights PayPal Holdings, Zoetis, CSX, Northrop Grumman, and The Kraft Heinz
For Immediate Release
Chicago, IL – April 18, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PayPal Holdings, Inc. (PYPL - Free Report) , Zoetis Inc. (ZTS - Free Report) , CSX Corp. (CSX - Free Report) ,Northrop Grumman Corp. (NOC - Free Report) , and The Kraft Heinz Co. (KHC - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for PayPal, Zoetis and CSX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc., Zoetis Inc., and CSX Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
PayPal shares have declined -61.8% over the past year against the Zacks Internet - Software industry's decline of -47.3% as sentiment has soured on growth stocks whose full profitability is way out in the future in a rising interest rate environment. The Zacks analyst points out to intensifying competition in the digital payment market as a headwind for the company's market position.
However, PayPal continues to benefit from robust growth in total payments volume owing to increasing net new active accounts. Further, strengthening customer engagement on the company's platform is a major positive.
Venmo's improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind.
(You can read the full research report on PayPal here >>>)
Shares of Zoetis have outperformed the Zacks Medical - Drugs industry over the past year (+14.2% vs. -22.4%). The Zacks analyst believes that an innovative portfolio of petcare parasiticides, including Simparica Trio and dermatology products (Apoquel and Cytopoint) will help the company's continued momentum. The uptake of Librela and Solensia, its new monoclonal antibody (mAb) therapies for osteoarthritis (OA) pain in dogs and cats, is encouraging in Europe and should boost growth. Zoetis' companion animal portfolio maintains momentum.
The launch of innovative products (ProHeart, Librela, Revolution Plus and many vaccines) bolstered the portfolio and should fuel growth in the upcoming quarters. However, the livestock portfolio has been affected by generic competition across cattle, poultry, swine, and dairy consumer markets in the United States. Pricing pressure will continue to hurt sales, which is a woe.
(You can read the full research report on Zoetis here >>>)
Shares of CSX have outperformed the Zacks Transportation - Rail industry over the past year (+7.7% vs. +4.9%). The Zacks analyst believes that due to healthy freight environment, CSX is benefiting from higher export coal volumes, international intermodal shipments, and pricing gains. The company's Volumes rose 6% in 2021, leading to an 18% jump in revenues, efforts to reward shareholders are encouraging. In February, CSX hiked its dividend by 7.5%.
The company returned over $3.7 billion to shareholders via dividends and share buybacks. However, supply chain disruptions are hurting CSX's operations. Weakness in the merchandise segment due to lower automotive volumes is concerning. High costs, primarily due to escalating fuel expenses, pose a threat to CSX's bottom line. The company's high capital expenditures are also worrisome.
(You can read the full research report on CSX here >>>)
Other noteworthy reports we are featuring today include Northrop Grumman Corp., and The Kraft Heinz Co..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.